{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:06:44Z","timestamp":1789330004718,"version":"build-2803163510"},"reference-count":110,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Medullary thyroid carcinoma (MTC) is a rare neuroendocrine neoplasm derived from parafollicular C cells of the thyroid gland, primarily driven by alterations in the rearranged during transfection (RET) oncogene. This review focuses on the current advances in treatment modalities for MTCs, encompassing surgical interventions, targeted therapy, postoperative surveillance, and future challenges. Total thyroidectomy is the primary curative approach for MTCs. However, the extent of lymph node dissection, particularly lateral neck dissection, remains controversial. Postoperative surveillance involves monitoring serum calcitonin and carcinoembryonic antigen levels, imaging assessments, and dynamic risk stratification to detect recurrence. Drug therapy offers an alternative approach in cases of challenging surgical scenarios or advanced MTCs. Multi-kinase inhibitors (e.g. vandetanib and cabozantinib) have shown increased survival outcomes for metastatic MTCs and are approved as effective treatment options. More recently, selective rearranged during transfection inhibitors like selpercatinib and pralsetinib have demonstrated higher efficacy and better tolerability. Despite these advances, challenges persist in managing MTCs, including addressing biochemical recurrence, determining surgical scope, considering immunotherapy, and treating advanced cases. Personalized medicine approaches, incorporating genetic screening, and innovative therapies, are essential for improving survival and quality of life in MTC patients.<\/jats:p>","DOI":"10.1097\/js9.0000000000002816","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T09:01:44Z","timestamp":1750755704000},"page":"7072-7086","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Dynamic risk stratification-guided management of medullary thyroid carcinoma: integrating surgical precision with RET-targeted therapies and molecular surveillance"],"prefix":"10.1097","volume":"111","author":[{"given":"Jiao","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Engineering Laboratory of Thyroid Disease Prevention and Control, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianlorenzo","family":"Dionigi","sequence":"additional","affiliation":[{"name":"Division of Surgery, Istituto Auxologico Italiano IRCCS, Milan, Italy"},{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon Yub","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, KUMC Thyroid Center, Korea University Hospital, Korea University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Engineering Laboratory of Thyroid Disease Prevention and Control, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0649-5449","authenticated-orcid":false,"given":"Changlin","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Engineering Laboratory of Thyroid Disease Prevention and Control, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejca.2017.07.015","article-title":"Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: a EUROCARE-5 study","volume":"84","author":"Minicozzi","year":"2017","journal-title":"Eur J Cancer"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"JAMA"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2023","journal-title":"JAMA"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman","year":"2006","journal-title":"Cancer"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/jcem-19-1-152","article-title":"Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity","volume":"19","author":"Hazard","year":"1959","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jmedgenet-2016-103833","article-title":"New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations","volume":"53","author":"Romei","year":"2016","journal-title":"J Med Genet"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2265.1996.681503.x","article-title":"Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma","volume":"44","author":"Marsh","year":"1996","journal-title":"Clin Endocrinol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.molcel.2014.01.015","article-title":"Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans","volume":"53","author":"Plaza-Menacho","year":"2014","journal-title":"Molecular Cell"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12964-024-01837-x","article-title":"Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"E2031","DOI":"10.1210\/jc.2012-2092","article-title":"Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon","volume":"97","author":"Boichard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/XCS.0000000000001098","article-title":"Genomic and transcriptomic landscape of ret wild-type medullary thyroid cancer and potential use of mitogen-activated protein kinase-targeted therapy","volume":"239","author":"Darabi","year":"2024","journal-title":"J Am Coll Surg"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s11864-023-01145-5","article-title":"The evolving treatment landscape of medullary thyroid cancer","volume":"24","author":"Lagan\u00e0","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.21037\/gs-23-284","article-title":"Chinese guidelines on intraoperative neuromonitoring in thyroid and parathyroid surgery (2023 edition)","volume":"12","author":"Sun","year":"2023","journal-title":"Gland Surg"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"203","DOI":"10.20892\/j.issn.2095-3941.2017.0051","article-title":"2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma","volume":"14","author":"Gao","year":"2017","journal-title":"Cancer Biol Med"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1507\/endocrj.EJ20-0025","article-title":"The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: core questions and recommendations for treatments of thyroid cancer","volume":"67","author":"Ito","year":"2020","journal-title":"Endocr J"},{"key":"R21-20260109","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.3390\/cancers14153643","article-title":"Update on the diagnosis and management of medullary thyroid cancer: what has changed in recent years?","volume":"14","author":"Kaliszewski","year":"2022","journal-title":"Cancers"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/cen.14739","article-title":"Suboptimal accuracy of ultrasound and ultrasound-based risk stratification systems in detecting medullary thyroid carcinoma should not be overlooked. Findings from a systematic review with meta-analysis","volume":"97","author":"Ferrarazzo","year":"2022","journal-title":"Clin Endocrinol"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000515373","article-title":"Diagnostic challenges of medullary thyroid carcinoma","volume":"99","author":"Leimbach","year":"2021","journal-title":"Oncology"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3747\/co.26.5539","article-title":"Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines","volume":"26","author":"Thomas","year":"2019","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1089\/thy.2019.0785","article-title":"Early diagnosis of medullary thyroid cancer: are calcitonin stimulation tests still indicated in the era of highly sensitive calcitonin immunoassays?","volume":"30","author":"Niederle","year":"2020","journal-title":"Thyroid"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3892\/ol.2021.12822","article-title":"Clinical value of color Doppler ultrasound combined with serum tumor markers for the diagnosis of medullary thyroid carcinoma","volume":"22","author":"Yang","year":"2021","journal-title":"Oncol Lett"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12020-021-02892-x","article-title":"Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis","volume":"75","author":"Trimboli","year":"2022","journal-title":"Endocrine"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.rcl.2020.07.004","article-title":"Computed tomography and MR imaging of thyroid disease","volume":"58","author":"Traylor","year":"2020","journal-title":"Radiol Clin North Am"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1210\/jc.2009-2368","article-title":"Biomarker-based risk stratification for previously untreated medullary thyroid cancer","volume":"95","author":"Machens","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study","volume":"7","author":"Castinetti","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s11845-021-02886-8","article-title":"Surgical aspects and controversies in the management of medullary thyroid cancer","volume":"191","author":"Green","year":"2022","journal-title":"Ir J Med Sci"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ecl.2018.11.006","article-title":"Management of medullary thyroid cancer","volume":"48","author":"Viola","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"e2346","DOI":"10.1210\/clinem\/dgaa246","article-title":"Foundation one genomic interrogation of thyroid cancers in patients with metastatic disease requiring systemic therapy","volume":"105","author":"I\u00f1iguez-Ariza","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"681","DOI":"10.47162\/RJME.61.3.06","article-title":"Medullary thyroid cancer: molecular factors, management and treatment","volume":"61","author":"Pavlidis","year":"2020","journal-title":"Rom J Morphol Embryol"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s002680010226","article-title":"Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma","volume":"24","author":"Miyauchi","year":"2000","journal-title":"World J Surg"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1017\/S0022215116000578","article-title":"Management of thyroid cancer: United Kingdom national multidisciplinary guidelines","volume":"130","author":"Mitchell","year":"2016","journal-title":"J Laryngol Otol"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","article-title":"FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"865911","DOI":"10.3389\/fendo.2022.865911","article-title":"Real-world evidence on the sensitivity of preoperative ultrasound in evaluating central lymph node metastasis of papillary thyroid carcinoma","volume":"13","author":"Yao","year":"2022","journal-title":"Front Endocrinol"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijsu.2017.04.026","article-title":"Timing and extension of lymphadenectomy in medullary thyroid carcinoma: a case series from a single institution","volume":"41","author":"Polistena","year":"2017","journal-title":"Int J Surg (London, England)"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1002\/bjs.10746","article-title":"Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations","volume":"105","author":"Machens","year":"2018","journal-title":"Br J Surg"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"549","DOI":"10.6004\/jnccn.2010.0042","article-title":"Medullary thyroid carcinoma: management of lymph node metastases","volume":"8","author":"Moley","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cncr.29761","article-title":"Surgery for lymph node metastases of medullary thyroid carcinoma: a review","volume":"122","author":"Jin","year":"2016","journal-title":"Cancer"},{"key":"R45-20260109","doi-asserted-by":"crossref","first-page":"20420188211049611","DOI":"10.1177\/20420188211049611","article-title":"Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis","volume":"12","author":"Bartz-Kurycki","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R46-20260109","first-page":"1012","article-title":"Chinese expert consensus on the diagnosis and treatment of medullary thyroid carcinoma (2020 edition)","volume":"40","author":"Wang","year":"2020","journal-title":"Chinese J Pract Sur"},{"key":"R47-20260109","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1245\/s10434-021-09683-8","article-title":"Prophylactic lateral neck dissection for medullary thyroid carcinoma is not associated with improved survival","volume":"28","author":"Spanheimer","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R48-20260109","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hed.24969","article-title":"Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer","volume":"40","author":"Pena","year":"2018","journal-title":"Head Neck"},{"key":"R49-20260109","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/coa.14053","article-title":"The survival outcomes of prophylactic lateral neck dissection for medullary thyroid carcinoma, a retrospective cohort study","volume":"48","author":"Hao","year":"2023","journal-title":"Clin Otolaryngol"},{"key":"R50-20260109","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anl.2018.08.017","article-title":"Significance of neck dissection for the treatment of clinically-evident medullary thyroid carcinomas: a systematic review","volume":"46","author":"Ahn","year":"2019","journal-title":"Auris Nasus Larynx"},{"key":"R51-20260109","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000499018","article-title":"The role of calcitonin in predicting the extent of surgery in medullary thyroid carcinoma: a nationwide population-based study in Norway","volume":"8","author":"Opsahl","year":"2019","journal-title":"Eur Thyroid J"},{"key":"R52-20260109","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/bjs\/znaa047","article-title":"Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction","volume":"108","author":"Niederle","year":"2021","journal-title":"Br J Surg"},{"key":"R53-20260109","doi-asserted-by":"crossref","first-page":"108881","DOI":"10.1016\/j.surg.2024.05.063","article-title":"Is desmoplastic stromal reaction useful to modulate lymph node dissection in sporadic medullary thyroid carcinoma?","volume":"177","author":"Procopio","year":"2025","journal-title":"Surgery"},{"key":"R54-20260109","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jcem-50-5-967","article-title":"Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma","volume":"50","author":"Deftos","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"R55-20260109","doi-asserted-by":"crossref","first-page":"991876","DOI":"10.3389\/fendo.2022.991876","article-title":"Meta-analysis of TSH suppression therapy and the risk of cardiovascular events after thyroid cancer surgery","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R56-20260109","doi-asserted-by":"crossref","first-page":"101655","DOI":"10.1016\/j.beem.2022.101655","article-title":"Medullary thyroid cancer - an update","volume":"37","author":"Fugazzola","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R57-20260109","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-319-22542-5_10","article-title":"Long-term follow-up in medullary thyroid carcinoma","volume":"204","author":"Raue","year":"2015","journal-title":"Recent Results Cancer Res"},{"key":"R58-20260109","first-page":"3634","article-title":"Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma","volume":"106","author":"Giovanella","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R59-20260109","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1245\/s10434-014-4102-y","article-title":"Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis","volume":"22","author":"Rowland","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R60-20260109","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1210\/jc.2019-00516","article-title":"Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of experience at one center","volume":"104","author":"Raue","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R61-20260109","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/bjs\/znab106","article-title":"Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels","volume":"108","author":"Fanget","year":"2021","journal-title":"Br J Surg"},{"key":"R62-20260109","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R63-20260109","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2006-1590","article-title":"Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules","volume":"92","author":"Costante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R64-20260109","first-page":"137","article-title":"Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer","volume":"63","author":"Andrade","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"R65-20260109","doi-asserted-by":"crossref","first-page":"1301260","DOI":"10.3389\/fendo.2024.1301260","article-title":"Central hyperthyroidism due to an ectopic TSH-secreting pituitary tumor: a case report and literature review","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Endocrinol"},{"key":"R66-20260109","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s00259-024-06639-4","article-title":"Gallium-68 labeled somatostatin receptor antagonist PET\/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China","volume":"51","author":"Liu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R67-20260109","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3390\/diagnostics14222608","article-title":"\u201cRosary Sign\u201d at somatostatin receptor pet in a case of recurrent meningioma","volume":"14","author":"Iacovitti","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R68-20260109","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2967\/jnumed.124.268877","article-title":"Safety, biodistribution, and radiation dosimetry of the 68ga-labeled minigastrin analog dota-mgs5 in patients with advanced medullary thyroid cancer and other neuroendocrine tumors","volume":"66","author":"von Guggenberg","year":"2025","journal-title":"J Nucl Med"},{"key":"R69-20260109","first-page":"59","article-title":"Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma","volume":"31","author":"Koperek","year":"2007","journal-title":"Int J Oncol"},{"key":"R70-20260109","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1089\/thy.2023.0008","article-title":"Head-to-head comparison of [(68)Ga]Ga-DOTA.SA.FAPi and [(68)Ga]Ga-DOTANOC positron emission tomography\/computed tomography imaging for the follow-up surveillance of patients with medullary thyroid Cancer","volume":"33","author":"Ballal","year":"2023","journal-title":"Thyroid"},{"key":"R71-20260109","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-24-0897","article-title":"CTR-FAPI PET enables precision management of medullary thyroid carcinoma","volume":"15","author":"Kong","year":"2025","journal-title":"Cancer Discov"},{"key":"R72-20260109","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"R73-20260109","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"R74-20260109","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12020-015-0849-6","article-title":"Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy","volume":"53","author":"Kwon","year":"2016","journal-title":"Endocrine"},{"key":"R75-20260109","doi-asserted-by":"crossref","first-page":"R387","DOI":"10.1530\/ERC-17-0270","article-title":"Dynamic risk stratification in the follow-up of thyroid cancer: what is still to be discovered in 2017?","volume":"24","author":"Krajewska","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"R76-20260109","doi-asserted-by":"crossref","first-page":"e9686","DOI":"10.1097\/MD.0000000000009686","article-title":"Dynamic risk stratification in medullary thyroid carcinoma: single institution experiences","volume":"97","author":"Choi","year":"2018","journal-title":"Medicine"},{"key":"R77-20260109","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.oraloncology.2013.03.443","article-title":"Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging","volume":"49","author":"Tuttle","year":"2013","journal-title":"Oral Oncol"},{"key":"R78-20260109","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archsurg.138.4.409","article-title":"Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship","volume":"138","author":"Yip","year":"2003","journal-title":"Arch Surg"},{"key":"R79-20260109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.21147\/j.issn.1000-9604.2017.03.08","article-title":"Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study","volume":"29","author":"Zhang","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"R80-20260109","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/thy.2014.0277","article-title":"Response to initial therapy predicts clinical outcomes in medullary thyroid cancer","volume":"25","author":"Lindsey","year":"2015","journal-title":"Thyroid"},{"key":"R81-20260109","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"R82-20260109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23080","article-title":"Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model","volume":"23","author":"Tappenden","year":"2019","journal-title":"Health Technol Assess"},{"key":"R83-20260109","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II Trial of the multitargeted tyrosine kinase inhibitor lenvatinib (e7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R84-20260109","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid"},{"key":"R85-20260109","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1089\/thy.2019.0453","article-title":"Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial","volume":"30","author":"Chen","year":"2020","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"R86-20260109","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/cncr.30252","article-title":"Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer","volume":"122","author":"Sherman","year":"2016","journal-title":"Cancer"},{"key":"R87-20260109","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J Clin Oncol"},{"key":"R88-20260109","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"R89-20260109","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"R90-20260109","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"key":"R91-20260109","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"key":"R92-20260109","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J Clin Oncol"},{"key":"R93-20260109","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R94-20260109","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"R95-20260109","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with ret-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"R96-20260109","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R97-20260109","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41392-024-02006-9","article-title":"First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R98-20260109","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s40265-024-02040-5","article-title":"RET inhibitors in ret fusion-positive lung cancers: past, present, and future","volume":"84","author":"Chen","year":"2024","journal-title":"Drugs"},{"key":"R99-20260109","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"R100-20260109","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R101-20260109","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"key":"R102-20260109","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol"},{"key":"R103-20260109","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/genes11111342","article-title":"Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks","volume":"11","author":"\u015amiech","year":"2020","journal-title":"Genes"},{"key":"R104-20260109","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3390\/genes12101534","article-title":"Immune profiling of medullary thyroid cancer-an opportunity for immunotherapy","volume":"12","author":"Hi\u0144cza-Nowak","year":"2021","journal-title":"Genes (Basel)"},{"key":"R105-20260109","doi-asserted-by":"crossref","first-page":"10019","DOI":"10.3390\/ijms241210019","article-title":"CD276 as a candidate target for immunotherapy in medullary thyroid cancer","volume":"24","author":"Hi\u0144cza-Nowak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R106-20260109","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1210\/clinem\/dgaa701","article-title":"Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: a large cohort study","volume":"106","author":"Shi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R107-20260109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0194599820947696","article-title":"External beam radiotherapy for medullary thyroid cancer following total or near-total thyroidectomy","volume":"164","author":"Jin","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R108-20260109","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1054\/bjoc.2000.1314","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d\u2019Etude des tumeurs \u00e0 calcitonine (GETC)","volume":"83","author":"Nocera","year":"2000","journal-title":"Br J Cancer"},{"key":"R109-20260109","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3109\/0284186X.2016.1157264","article-title":"Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?","volume":"55","author":"Marchand","year":"2016","journal-title":"Acta Oncol"},{"key":"R110-20260109","doi-asserted-by":"crossref","first-page":"R499","DOI":"10.1530\/ERC-18-0574","article-title":"Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives","volume":"26","author":"Ceolin","year":"2019","journal-title":"Endocr Relat Cancer"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:01:53Z","timestamp":1767963713000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":110,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002816","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"2025-03-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}